An important unanswered question in human immunodeavailable vaccine candidates represent only one of the multificiency virus type I (HIV-l) vaccine development is pie genetic subtypes of HlIV-I that exist worldwide. whether the considerable genetic variability of HIV-1 has
To gain a better understanding of the relationship between immunologic relevance. Analysis of the DNA sequence of genetic diversity (genotypes) and antigenic diversity (serointernationally collected HIV-I isolates reveals at least five types), we did cross-neutralization experiments with plasma genetically distinct subtypes that are widely disbursed and and viruses representing two distinct HIV-I genotypes. In intermixed geographically [1] [2] [3] [4] . If these genotypes correseveral previous reports, serum or plasma from HIV-I-inspond to antigenically distinct serotypes, then to be effective, fected individuals from various geographic locales demonany candidate vaccine will have to induce an immune restrated strong binding and neutralizing activity to one particsponse to a wide range ofantigenically diverse isolates. Most ular laboratory strain, HIV-I m. It was therefore postulated vaccine development efforts have focused on several protothat viruses prevalent in most parts of the world were antitype (laboratory) HIV-I strains obtained from individuals in genically similar to North American or European HIV-I with NHS control wells) was plotted against the reciprocal Plasma was recovered by centrifugation at 300 g for 15 min and plasma dilution (defined as the dilution of plasma in the presstored in I-mL aliquots at -70"C. Virus was isolated by cocultience of virus). The 50 11c neutralization titer was determined with vation of Ficoll-separated PBMC with phytohemagglutinin a curve fit program using the median effect equation (Biosoft. (PHA)-stimulated donor PBMC as previously described [18] .
Milltown, NJ) and values were rounded to the nearest 10. Four additional virus isolates and plasma were obtained from HIV-I-seropositive persons in the United States. For expansion Results to high-titered virus stocks, culture supernatant from the initial virus isolation was used to infect 2 X 107 fresh PHA-stimulated Genetic charact eri-ation otvirus isolates. Because neutraldonor PBMC. Cultures were followed for production of p figure I were based on a gpl60 DNA and predicted protein was used to infect human PBMC as described above, sequence alignment for the isolates used in this study and Genetic characteri:ation of virus isolates. Each of the 10 prisequences published in the Los Alamos sequence data bank mary HIV-I isolates was genetically characterized by full gp160
[1]. DNA-and protein-based trees have very similar topol-DNA sequence and phylogenetic tree analysis. DNA from ogy. Five genotypes are easily discerned (vertical bars). The PBMC cocultures was PCR amplified with primers flanking the viruses used in this study belonged to the genotypes numemv gene ofHIV-I as previously described [ 171, except that PCR bered I and 2. Two of the Thai isolates and the 4 US isolates primers(given 5'-3')wereJL86(CCGTCTAGATGCTGTTTAclustered in a single genetic subtype. together with labora-TTCATTTCAGAATTGG) and JL89 (TCCAGTCCCCCCtory isolates HIV-iMN, HIV-ILAI, HIV-lys-, and HIV-iRF(ge-TTTTCTTTTAAAAA). Molecular cloning and DNA sequencnotype I). The four other Thai viruses clustered ciosely toing (373A DNA sequencer; Applied Biosystems, Foster City, gether in a genetically distinct subtype (genotype 2). Thus. CA) were done as previously described [4. 17] . The eni' gene sequence and predicted protein sequence of the 6 Thai and 4 US these viruses represent two of the five genetic subtypes deisolates were compared with sequences published in the Los picted in figure I . On average, viruses in genotypes I and 2 Alamos sequence data bank [I] . Alignment of the sequences differed from each other by 20%c on the DNA level and 31 % was with CLUSTAL V. pairwise nucleotide distances were with on the protein level. DNADIST (PHYLIP 3.5. Kimura two-parameter model), proCross-neutralization evxperiments. Cross-neutralization assays tein distances were with PROTDIST (PHYLIP 3.5, Dayhoff were done with a panel of 8 plasma specimens obtained from PAM matrix), and the neighbor joining trees were with NEIGHclinically asymptomatic young men. These men were in-BOR (PHYLIP 3.5) [19] . The chimpanzee simian immunodefifected with viruses representing the two divergent genetic ciency virus isolate was used as an outgroup isolate to root the subtypes: that is, 4 US and 4 Thai plasma specimens each tree (not shown).
were from donors infected with HIV-l of genotype I and 2
Virus titration and neutralization assavs. To minimize variability between experiments, PBMC from a single donor were (figure I) [17] . For genotype I. plasma samples and virus cryopreserved and used for all titration and neutralization exisolates were obtained from the same individuals. For genoperiments. The TCID 50 was determined for each virus stock ustype 2, Thai plasma was not available for some virus isolates ing an assay designed to simulate the neutralization assay. In expanded for neutralization: thus, plasma and virus isolates neutralization experiments, six fourfold dilutions of heat-inactiare from different individuals. All 8 plasma samples reacted vated plasma (41-46) were aliquoted in quadruplicate in a 96-strongly on standard Western blot (Biotek Research Laborawell plate (40 ,L per well). To keep plasma protein concentratories, Rockville, MD; data not shown). These 8 plasma samtion constant, dilutions were done in culture media (RPMI 1640 pies were assayed against the 10 primary isolates of both supplemented with 15% fetal calf serum, penicillin, streptomygenotypes and against 3 laboratory strains (HIV-l 11 1 B, HIVcin. and L-glutamine) containing 25% pooled. heat-inactivated, IMN. and HIV-IRF). Each plasma sample was tested against normal human serum (NHS). Sextuplicate control wells conseveral viruses in two or three independent experiments. and tained medium with 25% NHS. An equal volume of virus stock, results were similar. Since only -30% of HIV-1 strains will representing 100 TCID5, was added to each well. After 30 min at 37 0 C. 2 X 10' PHA-stimulated PBMC were added and incuinfect standard human neoplastic T cell lines [23] [24] [25] . pribated overnight at 37*C. Cells were then washed three times by mary human PBMC were used as target cells in the neutralcentrifugation in l-mL cluster tubes (Costar, Cambridge. MA) ization assay. Laboratory strains were included in the crossto remove p24 antigen and plasma anti-p24 antibody. After the neutralization analysis because most prior neutralization final wash. cells were transferred to a 96-well microtiter plate studies have used these strains. Also, studies with sCD4 (the J ID 1994:169 (January) soluble form of the cell receptor for HIV-I) have shown that <10 to 790. As a group, plasma neutralization titers were in contrast to primary isolates, laboratory strains are highly significantly higher against viruses of the same genotype. US sensitive to sCD4 neutralization [26] . The three laboratory plasma samples (genotype I) had higher neutralization titers strains evaluated belong to genotype I. Several attempts to against US and Thai viruses of genotype I (geometric mean. generate a genotype 2 laboratory strain by passage of Thai 108 and 250, respectively) than against Thai viruses ofgenoviruses into neoplastic cell lines (H9. HuT-78. CEM) were type 2 (geometric mean, 12). Likewise, Thai plasma samples unsuccessful.
(genotype 2) reacted more strongly to the 4 Thai viruses of Figure 2 compares neutralization curves for 2 genetically genotype 2 (geometric mean, 96) than against US or Thai distinct virus isolates (US4 and T235) and 4 plasma samples.
genotype I viruses (8 and 6, respectively). For each virus Each data point represents the percentage decrease in p24 isolate, the neutralization profile correlated with the known antigen levels based on the mean value from quadruplicate genotype. Thus, the 2 Thai viruses characterized as genotype wells. In these experiments. the median coefficient of varia-I had a neutralization profile similar to the US viruses of the tion for p2 4 antigen production in quadruplicate wells was same genotype. Between different genotypes, plasma were 2 1%. The 2 US plasma samples (genotype I) exhibited strong often nonneutralizing even at the lowest dilution tested ( 1:8, neutralizing activity against the homotypic US virus but subfigure 2). Even with some variability among individual stantially weaker activity against the genotype 2 Thai virus, plasma samples, the geometric mean titers from plasma and Likewise, the 2 Thai plasma samples (genotype 2) exhibited virus of the same genotype were --10-fold higher than those significant neutralizing activity only against the genotype 2 obtained from plasma and virus from heterologous genoThai virus. types (figure 3). Thus, for the two genotypes of HIV-I studAs shown in table I and figure 3, 50% neutralization titers ied, genetic subtype correlated with an antigenically distinct for all 8 plasma samples against primary isolates ranged from viral serotype. Plasma samples were also assayed against genotype I vicompared with 150 against US primary isolates. Likewise, ruses represented by the laboratory strains HIV-I mN, HIVthe geometric mean titer for Thai plasma against laboratory I nB, and HIV-I RF (table I) . Like the primary HIV-I isolates, strains was 150 compared with 8 and 6, respectively, against these viruses were more strongly neutralized by genotype I US and Thai primary isolates of genotype 1.
plasma. The geometric mean titer of US plasma samples against laboratory strains was 3360 compared with 150 for Discussion the heterotypic Thai plasma samples (figure 3). However, in contrast to primary HIV-I isolates, the laboratory strains While there is abundant evidence for multiple genetic subwere significantly more susceptible to neutralization by types of HIV-I. the immunologic significance of divergent plasma samples of both genotypes. The geometric mean titer genotypes has not been well studied. This report is the first to of US plasma samples against laboratory strains was 3360 clearly demonstrate a correlation between HIV-I genotype 790  20  90  90  30  68,000  1300  1300  Genotype 2  T241  10  <8  10  10  <8  <8  80  130  30  30  120  60  40  T239  40  10  <8  <8  20  <8  680  100  350  160  340  60  50  T245  20  <8  20  <8  <8  <8  110  110  20  100  980  210  240  T235  10  <8  20  10  <8  <8  140t  140  40  50  510  130  150 NOTE. Values represent reciprocal plasma dilution that reduced p24 expression by 50% in phytohemagglutinin-stimulated peripheral blood mononuclear cells.
* Neutralization with autologous plasma obtained at same time virus was isolated. Neutralization with autologous plasma obtained -I year after virus was isolated. and antigenic phenotype. The 10 primary HIV-I isolates we onstrated recently that human lymphocyte antigens (HLA) evaluated represent two distinct genetic subtypes as deterare physically associated with HIV-I virions, and antisera to mined by DNA sequence analysis of the full env gp 160 gene.
A. U.S. PLASMA SAMPLES (GENOTYPE 1)
HLA class I, HLA-DR. and 6i2-microglobulin can inhibit Using a PBMC-based neutralization assay, we were able to infection of cultured cells by . demonstrate that for each virus, neutralization serotype Furthermore, because of presumed molecular mimicry becorrelated with genetic subtype. In particular, the two Thai tween epitopes of HIV-I envelope glycoprotein and HLA viruses of genotype I displayed a neutralization phenotype antigens, sera from some HIV-I-infected persons contain similar to the US viruses of the same genotype. While this antibodies to HLA class II molecules [30, 31] . Thus. sera relationship between genotype and serotype has been evalufrom HIV-1-infected persons could theoretically contain ated for only two of the several HIV-I genotypes, data suganti-HLA antibodies that would neutralize HIV-I. Although gest that it may exist among other subtypes. Cheng-Mayer et PBMC from a single donor were used as target cells in our al. [271, using a PBMC neutralization assay, showed that sevneutralization assays, the virus stocks were obtained by exeral US-derived anti-HIV-I human sera reacted weakly. or pansion in PBMC from different donors. Therefore, virus not at all, to 3 virus isolates obtained in Rwanda. Also, other isolates from different genetic or antigenic subtypes could investigators evaluating binding antibody or neutralizing anpotentially present simila-cellular (HLA) antigens that theotibody to laboratory strains have shown reduced reactivity retically could be responsible for cross-neutralization. This between serum and virus or viral peptides from differing geohypothesis is currently being addressed. Regardless ofmechagraphic locales [II, 21. 281. nism, cross-neutralization between genotypes was uncomOf interest, I of the genotype I plasma specimens (US4) mon in our experiments. Also of note are the relatively low reacted strongly with 2 of 4 Thai viruses of genotype 2. This neutralization titers by autologous plasma against concomimay indicate the presence of neutralizing antibodies to a retantly obtained virus. This is seen in 3 of the 4 subjects for gion conserved among HIV-I subtypes. Delineation of the which there were concomitant autologous plasma and virus epitope or epitopes responsible for generating cross-reactive samples (US I, US2, and US3). This relative neutralization neutralizing antibodies could be an important contribution resistance is thought to be a manifestation of "neutralization to development of a broadly effective vaccine. Alternatively, escape" and has been previously described in lentivirus disit is possible that cross-reactivity is the result of antibodies to eases including HIV infection [32, 33]. human cellular antigens present on virions. It has been dem-
The neutralization experiments using laboratory strains HIV-[MN, HIV-1lun, and HIV-IRF demonstrated a marked genetic and, potentially, antigenic diversity. Our observation disparity in the ability of human plasma to neutralize laborathat HIV-l genotypes may represent antigenically distinct tory strains compared with primary isolates of HIV-i. As serotypes suggests, but does not prove, that immunization expected, US plasma neutralized laboratory strains more with an HIV-l strain representing one genotype will be inefstrongly than did the heterotypic Thai plasma. However, fective against heterologous subtypes. Such an evaluation when measured against laboratory strains, all plasma samcan be made only through in vivo vaccine challenge studies. pies displayed a greater magnitude and. importantly, breadth However, if inclusion of distinct HIV-I subtypes is required of neutralizing activity. In particular, US plasma samples for the development of a broadly effective vaccine, a more had neutralization titers 100 to 1000 times higher against inclusive and systematic effort to characterize the regional HIV-1MN than against primary isolates from the United prevalence of HIV-I genotypes and immunotypes may be a States, This disparity in sensitivity to neutralizing antibody is critical component of vaccine development. Furthermore, comparable to neutralization with sCD4. in which primary vaccine candidates representing each distinct subtype may isolates required 200 to 2700 times more sCD4 than was have to be constructed and evaluated for breadth ofimmunoneeded to inhibit laboratory strains [261. With respect to genicity in phase I trials in humans. A broadening of vaccine breadth of reactivity against divergent viruses, the Thai development efforts to include multiple genotypes or sero,-plasma samples (genotype 2) appear to have strong crosstypes may reap significant dividends as vaccines face the reactivity when assayed against genotype I laboratory strains challenges of HIV-I diversity. (geometric mean titer. 150) but have little cross-reactivity when assayed against genotype I primary isolates (geometric mean titer, 8: figure 3B ). Furthermore, the Thai plasma samAcknowledgments pies give neutralization titers against laboratory strains (150)
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